SS Innovations International (NASDAQ: SSII) has expanded its global footprint with the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the company's SSi Mantra 3.0 surgical robotic system, according to a recent press release. This development not only marks a milestone for Sri Lanka's healthcare sector but also underscores SS Innovations' growing influence in the global surgical robotics market.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The successful launch of the program demonstrates the SSi Mantra's capability in complex cardiac procedures, potentially opening doors for broader adoption in other countries. Kings Hospital has already completed more than 25 robotic procedures in just three weeks, indicating rapid uptake and proficiency with the system.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These figures point to rising utilization of the company's installed base, which is crucial for recurring revenue and long-term growth. The expansion into Sri Lanka adds another country to SS Innovations' roster and demonstrates the versatility of the SSi Mantra system in different healthcare environments.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would allow the company to enter two of the largest and most lucrative medical device markets in the world. The successful implementation in Sri Lanka could serve as a reference case for regulators and healthcare providers in other regions, showcasing the system's safety and efficacy in a real-world setting.
For investors, the news signals SS Innovations' ability to execute on its international growth strategy. The company's stock, traded on NASDAQ under the ticker SSII, may see increased attention as it approaches key regulatory milestones. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Additionally, detailed disclaimers and terms of use can be found at https://IBN.ai/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially. These include factors beyond management's control, such as regulatory approvals and market acceptance. Undue reliance should not be placed on these statements when making investment decisions.
